Registration
 
All news
Top Stories
Editors' Picks
Crypto News
Financial News
Currencies
Market Voices
Billionaires
Companies
Regulators News
Ashutosh Sureka
Ashutosh Sureka

Regeneron unveils Phase 2 data in The Lancet improving heart health

Regeneron unveils Phase 2 data in The Lancet improving heart health
@Regeneron: Regeneron unveils data in The Lancet

Regeneron Pharmaceuticals has released Phase 2 data on its novel investigational factor XI antibodies, marking a significant step in heart health research. The data was published in The Lancet and presented at the American Heart Association Scientific Sessions.

The release underscores Regeneron's commitment to pioneering treatments in cardiovascular care, potentially paving the way for future innovations. The company's investigational efforts aim to address unmet medical needs in the treatment of heart-related conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • By Eugene Komchuk
  • 1 hour ago
Five years with Bitcoin: How El Salvador changed after legalizing BTC
Editors' Picks
Crypto on the court: How NBA Finals became a showcase for Ledger
  • By Anastasiia Chabaniuk
  • Yesterday
Crypto on the court: How NBA Finals became a showcase for Ledger
Editors' Picks
How to build wealth from scratch in 3 practical steps
  • By Johnathan Maverick
  • Yesterday
How to build wealth from scratch in 3 practical steps
Editors' Picks
All Editors' Top Picks

Latest Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%
  • By Ashutosh Sureka
  • Yesterday
Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%
Financial News
#Forecast #Regeneron Pharmaceuticals
Regeneron Pharmaceuticals shares dip amid rising selling pressure
  • By Sholanke Dele
  • 01.06.2026
Regeneron Pharmaceuticals shares dip amid rising selling pressure
Financial News
#Forecast #Regeneron Pharmaceuticals
Regeneron Pharmaceuticals stock consolidates as Global Capability Centre opening in Hyderabad draws focus
  • By Oleg Tkachenko
  • 26.05.2026
Regeneron Pharmaceuticals stock consolidates as Global Capability Centre opening in Hyderabad draws focus
Financial News
#Forecast #Regeneron Pharmaceuticals
All Regeneron Pharmaceuticals News
  • Eugene Komchuk
  • 1 hour ago
Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • Anastasiia Chabaniuk
  • Yesterday
Crypto on the court: How NBA Finals became a showcase for Ledger
  • Johnathan Maverick
  • Yesterday
How to build wealth from scratch in 3 practical steps
  • Eugene Komchuk
  • 08.06.2026
Kospi Index crash: Why South Korean market fell alongside AI stocks
  • Mira Kyivska
  • 07.06.2026
Bitcoin or Ferrari: Which investment is better?
  • Yaroslav Dmytrenko
  • 16 min ago
Banks move into crypto custody after years of warnings, Fernando Nikolic notes
  • Anastasiia Chabaniuk
  • 46 min ago
Bank of Japan policy shift will limit credit and raise borrowing costs, Daniel Lacalle argues
  • Ivan Andriyenko
  • 52 min ago
Dan Neidle: Stamp duty’s limited fiscal impact and major effect on daily life
  • Hlib Chabaniuk
  • 1 hour ago
George Selgin: FDR pushed deficit spending after 1937-8 recession
  • Hanna Syniavska
  • 2 hours ago
Gregory Raymond: 93 percent of leaders want AI agents but only 2 percent succeed due to payments
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Andrey Mastykin
  • 13 min ago
CLARITY Act talks hit new obstacles in Senate
CLARITY Act talks hit new obstacles in Senate
  • Anastasiia Chabaniuk
  • 1 hour ago
Trump family made $2.3B from crypto ventures as investors faced losses
Trump family made $2.3B from crypto ventures as investors faced losses
  • Olga Shendetskaya
  • 2 hours ago
U.S. strikes on Iran weigh on Wall Street
U.S. strikes on Iran weigh on Wall Street
  • Eugene Komchuk
  • 2 hours ago
Oil jumps to $93 after U.S. and Iran exchange strikes
Oil jumps to $93 after U.S. and Iran exchange strikes
  • Igor Krasulya
  • 18 hours ago
SpaceX-Google pact fuels debate over IPO valuation
SpaceX-Google pact fuels debate over IPO valuation
Live News
  • Mykhailo Ihnatenko
  • Now
Solana faces critical test as risk-off sentiment dominates crypto
  • Mykhailo Ihnatenko
  • Now
Crypto winter fears return as Bitcoin faces risk of 40% decline
  • Dmytro Kharkov
  • Now
IBM seeks fresh momentum after four-day losing streak
  • Anton Kharitonov
  • Now
Microsoft declines as market seeks returns on AI investments
  • Anton Kharitonov
  • Now
Apple declines after WWDC as investors expected more
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR